EXPLAINED: Lykos therapeutics | Rare Historical Photos

The FDA Just Put Psilocybin and an MDMA-Like Drug on a 1-to-2 Month Approval Track. A Historic Mental Health Decision Is Coming.

FDA issued National Priority Vouchers to Compass Pathways, Usona, and Transcend for psilocybin and methylone in April 2026. A decision could come by late 2026.

Medical Daily · Jun 17

Advocates of MDMA-Assisted Psychotherapy Complain that 'the FDA Moved the Goalposts'

The agency's puzzling concerns about the Lykos Therapeutics drug application

Reason · Sep 8, 2025

The Future of Psychedelic Research Is In Limbo — Why the FDA’s Decision Changed Everything

The FDA just rejected MDMA-assisted therapy for PTSD. What's next for psychedelic drugs in science and everyday life?

Inverse · Aug 17, 2024